Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Snake venom three-finger toxins (3FTxs) are a superfamily of non-enzymatic proteins characterized by a conserved structural scaffold consisting of three beta-stranded loops extending from a central hydrophobic core, stabilized by four or five disulfide bonds (Kini, 2002; Utkin, 2015). These toxins are the primary lethal components in the venoms of Elapid snakes, such as the Indian Cobra (Naja naja) and Common Krait (Bungarus caeruleus), where they function as potent alpha-neurotoxins that competitively inhibit nicotinic acetylcholine receptors (nAChR) at the neuromuscular junction (Senji Laxme et al., 2019; WHO, 2016). While 3FTxs are the dominant neurotoxic agents in Elapids, they are present in significantly lower concentrations or are absent in the venoms of Viperids like the Russell’s Viper (Daboia russelii) and Saw-scaled Viper (Echis carinatus), which are instead dominated by phospholipases and proteases (Senji Laxme et al., 2019). In the clinical management of snakebites from India's 'Big Four' snakes, 3FTxs are critical targets for polyvalent antivenoms, which utilize purified antibodies to sequester the toxins and prevent their binding to host receptors (WHO, 2016). Therapeutic challenges include the rapid onset of neurotoxicity, which may outpace antivenom administration, and the risk of severe allergic reactions to equine-derived antivenom treatments (WHO, 2016). Beyond their role in envenomation, 3FTxs are also studied for their ability to modulate ion channels and receptors with high specificity, making them valuable tools in pharmacological research and drug design (Kini, 2002).
Antivenoms neutralize 3FTxs by antibody-mediated sequestration, preventing the toxins from binding to nicotinic acetylcholine receptors (nAChR) or other cellular targets.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Snake venom three-finger toxin (3FTx).